Signals, Powered By EquityPandit
The US health regulator has provided its approval to Alembic Pharmaceuticals for Fenofibric Acid Delayed Release capsules that are used in lowering high cholesterol and increasing good cholesterol.
Alembic Pharma has said in a BSE filing that “The company has received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for its Fenofibric Acid Delayed-Release Capsules, 45mg and 135 mg.”
The product that has been approved is therapeutically equivalent to the reference listed drug product Trilipix Delayed Release capsules of Abbvie Inc.
